4-Iodo Suberoylanilide HydroxaMic Acid manufacturers
- 4-iodo-SAHA
-
- $323.00
-
2026-04-22
- CAS:1219807-87-0
- Purity:
- Supply Ability: 10g
|
| | 4-Iodo Suberoylanilide HydroxaMic Acid Basic information |
| | 4-Iodo Suberoylanilide HydroxaMic Acid Chemical Properties |
| density | 1.579±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | insoluble in H2O; insoluble in EtOH; ≥1.67 mg/mL in DMSO | | form | A crystalline solid | | pka | 9.48±0.20(Predicted) |
| | 4-Iodo Suberoylanilide HydroxaMic Acid Usage And Synthesis |
| Uses | A SAHA derivative with antiproliferative activity in several human cancer cell lines. Antitumor agent. | | Biological Activity | 4-iodo-saha is a hydrophobic derivative of saha, the class i and class ii histone deacetylase (hdac) inhibitor [1].the reversible acetylation of lysine residues in histone plays an important role in transcriptional activation and repression. the regulation of these post-translational modifications is balanced by histone acetyltransferase (hat) and histone deacetylase (hdac) activities. hdacs are also involved in reversible acetylation of non-histone proteins [1].4-iodo-saha is a histone deacetylase (hdac) inhibitor. in skbr3-breast-derived cell line, 4-iodo-saha inhibited cell proliferation with ec50 value of 1.1 μm. in ht29 colon-derived cell line, leukemia-derived u937 tumor cell line, ja16, hl60 and k562 cell lines, 4-iodo-saha inhibited cell proliferation with ec50 values of 0.95, 0.12, 0.24, 0.85 and 1.3 μm, respectively. 4-iodo-saha is 10-fold more potent as an inhibitor of u937 leukemia cell proliferation compared to saha (0.12 μm versus 1.2 μm). in skbr3 cells, 4-iodo-saha reduced acetylated h4 and p21 levels [1]. | | in vivo | 4-Iodo-SAHA (1k) (50 mg/kg; p.o. five times a week for two weeks) compares to SAHA-treated and control mice with similar toxicity[1]. | Animal Model: | 8-week-old fvb mice[1] | | Dosage: | 50 mg/kg | | Administration: | Oral gavage; 50 mg/kg five times per week; for 2 weeks | | Result: | Compared to both SAHA-treated and control mice with similar body weights and hematological counts. |
| | references | [1]. salmi-smail c, fabre a, dequiedt f, et al. modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity. j med chem. 2010 apr 22;53(8):3038-47. |
| | 4-Iodo Suberoylanilide HydroxaMic Acid Preparation Products And Raw materials |
|